Treatment options in pediatric epilepsy syndromes

Epileptic Disorders

Volumn 4, Issue 3, 2002, Pages 217-225

  Arzimanoglou, Alexis ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Antiepileptic drugs; Epilepsy; Epilepsy management; Epilepsy syndromes; Treatment

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CORTICOTROPIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HYDROCORTISONE; IMMUNOGLOBULIN; LAMOTRIGINE; NITRAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PYRIDOXINE; STEROID; STIRIPENTOL; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ABSENCE; ACNE; ALLERGY; ANAMNESIS; APLASTIC ANEMIA; CHRONIC TOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONSCIOUSNESS DISORDER; COOPERATION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DOCTOR PATIENT RELATION; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SPECIFICITY; ELECTROENCEPHALOGRAM; EPILEPSY; FOCAL EPILEPSY; HUMAN; IMAGING; INTOXICATION; KETOGENIC DIET; LIVER TOXICITY; MUSCLE SPASM; NERVE STIMULATION; ONSET AGE; PATIENT CARE; PATIENT INFORMATION; PATIENT SELECTION; PRIORITY JOURNAL; RECORDING; REVIEW; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; SUDDEN DEATH; SYNDROME; TREATMENT FAILURE; TREATMENT PLANNING; VAGUS NERVE; VIDEOTAPE; WEIGHT GAIN; WEIGHT REDUCTION; WEST SYNDROME;

ADRENOCORTICOTROPIC HORMONE; ANTI-INFLAMMATORY AGENTS; EPILEPSY; HUMANS; HYDROCORTISONE;

EID: 0036762390     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Aicardi J, Arzimanoglou A. Treatment of the childhood epilepsy syndromes. In: Shorvon SD, et al., eds. The Treatment of Epilepsy. Oxford: Blackwell Science, 1996: 199-214.
2. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia 1998; 39: 5-17.
3. Hirsch E, de Saint Martin A, Arzimanoglou A. New insights into the clinical management of partial epilepsies. Epilepsia 2000; 41 (suppl 5): S13-7.
4. Aicardi J. Epilepsy in Children, 2nd Edn. New York: Raven Press, 1994.
5. Mattson, RH, Cramer JA, Collins JF, et al. A Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic clonic seizure. N Engl J Med 1985; 313: 145-51.
6. Mattson RH, Cramer JA, Collins JF, Veterans Administration Epilepsy Cooperative Study Group. Comparisons between carbamazepine and valproate for complex partial and secondarily generalized tonic-clonic seizures. Epilepsia 1991; 32: 42-18.
7. Marson AG, Kadi ZA, Chadwick DW. New antiepileptic drugs. A systematic review of their efficacy and tolerability. Br Med J 1996; 313: 1169-74.
8. So EL, Lai CW, Pellock J, Mashman J, Brugger A. Safety and efficacy of valproate and carbamazepine in the treatment of complex partial seizures. J Epilepsy 1992; 5: 149-52.
9. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neuro Neurosurg Psychiatry 1982; 45: 55-9.
10. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985; 48: 639-44.
11. Callaghan N, O'Hare J, O'Driscoll D, O'Neill B, Daly M. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (Petit Mal). Dev Med Child Neurol 1982; 24: 830-6.
12. Cockerell OC, Johnson AL, Sander JWAS, Hart YM, Shorvon SD. Remission of epilepsy: Results from the National General Practice Study of Epilepsy. Lancet 1995; 346: 140-4.
13. Mattson RH, Cramer JA, Collins JF, and the Department of Veterans Affairs Epilepsy Cooperative studies N° 118 and N° 264 Group. Prognosis of total control of complex partial end secondary generalized tonic-clonic seizures. Neurology 1996; 47: 68-76.
14. Sillanpää M. Long-term outcome of epilepsy. Epileptic Disord 2000; 2: 79-88.
15. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9.
16. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255-60.
17. Bureau M, Kahane P, Munari C, eds. Épilepsies Partielles Graves Pharmaco-Résistantes de L'enfant: Stratégies Diagnostiques et Traitements Chirurgicaux. Paris: John Libbey Eurotext, 1998: 333.
18. Tuxhorn I, Holthausen H, Boenigk H, eds. Paediatric Epilepsy Syndromes and Their Surgical Treatment. London: John Libbey, 1997.
19. Aicardi J. Paediatric epilepsy surgery: How the view has changed. In: Tuxhorn I, Holthausen H, Boenigk H. Paediatric Epilepsy Syndromes and Their Surgical Treatment. London: John Libbey, 1997: 3-7.
20. Duchowny M. Pediatric epilepsy surgery: The widening spectrum of surgical candidacy. Epileptic Disord 1999; 1: 143-51.
21. Parker AP, Polkey CE, Binnie CD, Madigan C, Ferrie CD, Robinson RO. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics 1999; 103: 778-82.
22. Régis J, Bartolomei F, Hayashi M, Roberts D, Chauvel P, Peragut JC. The role of gamma knife surgery in the treatment of severe epilepsies. Epileptic Disord 2000; 2: 113-22.
23. Flask F, Velasco M, Velasco AL, Jimenez F, Marquez I, Rise M. Electrical stimulation of the centromedian thalamic nucleus in control of seizures: Long-term studies. Epilepsia 1995; 36: 63-71.
24. Weaver DF, Camfield P, Fraser A. Massive carbamazepine overdose: Clinical and pharmacologic observations in five episodes. Neurology 1988; 38: 755-9.
25. Zaret, BS, Cohen RA. Reversible valproic-acid induced dementia: A case report. Epilepsia 1986; 27: 234-40.
26. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52: 321-7.
27. Meador KJ, Loring DW, Moore EE, et al. Comparative cognitive effects of phenobarbital, phenytoin and valproate in healthy subjects. Neurology 1995; 45: 1494-9.
28. Meador KJ. Cognitive effects of epilepsy and of antiepileptic medications. In: Wyllie E. The Treatment of Epilepsy. Philadelphia: Lippincott Williams & Wilkins, 2001: 1215-25.
29. Murphy, JV, Sawasky, F, Marquardt, KM, Harris DJ. Deaths in young children receiving nitrazepam. J Pediatr 1987; 111: 145-7.
30. Stone S, Lange LS. Syncope and sudden unexpected death attributed to carbamazepine in a 20-year-old epileptic. J Neurol Neurosurg Psychiatry 1986; 49: 1460-1.
31. Leestma JE, Kalekar MB, Teas SS, et al. Sudden unexpected death in epilepsy: Observations from a large clinical development program. Epilepsia 1997; 38: 47-55.
32. Levy RH, Mattson RH, Meldrum BS. Antiepileptic Drugs, 4th Ed. New York: Raven Press, 1995.
33. Appleton RE, Farrell K, Applegarth DA, Dimmick JE, Wong LTK, Davidson AGF. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can J Neurol Sci 1990; 17: 145-8.
34. Dravet C, Dalla Bernardina B, Mesdjian E, Galland MC, Roger J. Dyskinésies paroxystiques au cours des traitements par la diphénylhydantoine. Rev Neurol (Paris) 1980; 136: 1-14.
35. Joyce RP, Gunderson CH. Carbamazepine-induced orofacial dyskinesia. Neurology 1978; 30: 1333-4.
36. Kaplan BJ, Wilder BJ, Hammond ET, Bauman AW. Valproate tremors. Neurology 1982; 32: 428-32.
37. McLachlan RS. Pseudoatrophy of the brain with valproic acid monotherapy. Can J Neurol Sci 1987; 14: 294-6.
38. McLeod CM, Dekaban AS, Hunt E. Memory impairment in epileptic patients: Selective effects of phenobarbital concentration. Science 1978; 202: 1102-4.
39. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987; 28 (suppl 3): S64-70.
40. Weig SG, Pollack P. Carbamazepine-indiced heart block in a child. Ann Neurol 1993; 34: 617-9.
41. Gerber PE, Hamiwka L, Connolly MB, et al. Factors associated with behavioral and cognitive abnormalities in children receiving topiramate. Pediatr Neurol 2000; 22: 200-3.
42. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65-9.
43. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J 1981; 283: 577-81.
44. De Toledo JC, Toledo C, DeCerce J, et al. Changes in body weight with chronic, high-dose, gabapentin therapy. Ther Drug Monit 1997; 19: 394-6.
45. Potter D, Edwards KR, Norton J. Sustained weight loss associated with 12-month topiramate therapy. Epilepsia 1997; 38 (suppl 8): 97.
46. Brown, JK. Valproate toxicity. Dev Med Child Neurol 1988; 30: 121-5.
47. Gilhus NE, Matte R. Carbamazepine effects on mononuclear blood cells in epileptic patients. Acta Neurol Scand 1986; 74: 181-5.
48. Kaufman DW, Kelly JP, Anderson T, et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997; 38: 1265-9.
49. Fernando-Calvo C, Olacoaga J, Resano A, et al. Lyell syndrome associated with lamotrigine. Rev Neurol 2000; 31: 1162-4.
50. Schlienger RG, Knowles SR, Shear NH. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998; 51: 1172-5.
51. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998; 39 (suppl 3): S2-10.
52. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39: 508-12.
53. Aldenkamp AP. Effects of antiepileptic drugs on cognition. Epilepsia 2001; 42 (suppl 1): 46-9.
54. Birbeck GL, Hays RD, Cui X, Vickrey B. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002; 43: 535-8.
55. Carpay HA, Vermeulen J, Stroink H, et al. Disability due to restrictions in childhood epilepsy. Dev Med Child Neurol 1997; 39: 521-6.
56. de Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, Johnson AL, Reynolds EH. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-13.
57. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The paeditric EPITEG collaborative Group. Dev Med Child Neurol 1995; 37: 97-108.
58. Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G, Garofalo E. Gabapentin as add-on therapy in children with refractory partial seizures: A 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia 1999; 40: 1147-54.
59. Appleton R, Fichtner K, LaMoreaux L, Alexander J, Maton S, Murray G, Garofalo E. Gabapentin as add-on therapy in children with refractory partial seizures: A 24-week, multicentre, open-label study. Dev Med Child Neurol 2001; 43: 269-73.
60. Besag FM, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995; 127: 991-7.
61. Arzimanoglou A, Kulak I, Bidaut-Mazel C, Baldy-Moulinier M. Utilisation optimale de la lamotrigine en pratique clinique: Résultats d'une étude ouverte multicentrique dans l'épilepsie réfractaire. Rev Neurol 2001; 157: 525-36.
62. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205-13.
63. Britton JW, So EL. Selection of antiepileptic drugs: A practical approach. Mayo Clin Proc 1996; 7: 778-86.
64. Guerrini R, Battini R, Ferrari AR, et al. The costs of childhood epilepsy in Italy: Comparative findings from three health care settings. Epilepsia 2001; 42: 641-6.
65. Arzimanoglou A, Thomas P, Durisotti C, Billard C, Hirsch E. Tentative d'évaluation des coûts médico-sociaux des épilepsies. In: Bureau M, Kahane P, Munari C, eds. Épilepsies Partielles Graves Pharmaco-Résistantes de L'enfant: Stratégies Diagnostiques et Traitements Chirurgicaux. Paris: John Libbey Eurotext, 1998: 87-97.
66. Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51: 1256-62.
67. Bourgeois M, Sainte-Rose C, Lellouch-Tubiana A, et al. Surgery of epilepsy associated with focal lesions in childhood. J Neurosurg 1999; 90: 833-42.
68. Arzimanoglou AA, Andermann F, Aicardi J, et al. Sturge-Weber syndrome: Indications and results of surgery in 20 patients. Neurology 2000; 55: 1472-9.
69. Dravet C, Guerrini R, Mancini J, Saltarelli A, Livet MO, Galland MC. Different outcomes of epilepsy due to cortical dysplastic lesions. In: Guerrini R, Andermann F, Canapicchi R, Roger J, Zifkin BG, Pfanner P, eds. Dysplasias of Cerebral Cortex and Epilepsy. Philadelphia: Lippincott-Raven, 1996: 323-8.
70. Tassi L, Colombo N, Garbelli R, et al. Focal cortical dysplasia: Neuropathological subtypes, EEG, neuroimaging and surgical outcome. Brain 2002; 125: 1719-32.
71. Camfield PR, Camfield CS. Treatment of children with "ordinary" epilepsy. Epileptic Disord 2000; 2: 45-51.
72. Wyllie E. Children with seizures: When can treatment be deferred? J Child Neurol 1994; 9 (suppl): 2S8-13.
73. Ambrosetto G, Tassinari CA. Antiepileptic drug treatment of benign childhood epilepsy with rolandic spikes: Is it necessary? Epilepsia 1990; 31: 802-5.
74. Doose H, Baier WK, Ernst JP, Tuxhorn I, Volzke E. Benign partial epilepsy-treatment with sulthiame. Dev Med Child Neurol 1988; 30: 683-4.
75. Bourgeois B, Brown L, Pellock J, et al. Gabapentin (Neurontin) monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): A 36-week, double-blind, placebo-controlled study. Epilepsia 1998; 39: 163.
76. Bourgeois BF. Drug treatment of benign focal epilepsies of childhood. Epilepsia 2000; 41: 1057-8.
77. Corda D, Gelisse P, Genton P, Dravet C, Baldy-Moulinier M. Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes. Epilepsia 2001; 42: 754-9.
78. Picard F, Bertrand S, Steinlein OK, Bertrand D. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. Epilepsia 1999; 40: 1198-209.
79. Panayiotopoulos CP, Ferrie CD, Knott C, et al. Interaction of lamotrigine with sodium valproate. Lancet 1993; 341: 445.
80. Schlumberger E, Chavez F, Palacios E, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359-67.
81. Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000; 12: 1758.
82. Gram L. Acetazolamide, benzodiazepines and lamotrigine. In: Duncan JS, Panayiotopoulos CP, eds. Typical Absences and Related Syndromes. London: Churchill Communication Europe, 1995: 368-75.
83. Munn R, Farrell K. Open study of clobazam in refractory epilepsy. Pediatr Neurol 1993; 9: 465-9.
84. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, Pledger G. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999; 52: 1330-7.
85. Rosenfeld WE. Topiramate: A review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997; 19: 1294-308.
86. Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, Edelbroek PM, Oosting J. Photosensitive epilepsy: A model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996; 25: 225-30.
87. Bauer J. Seizure-inducing effects of antiepileptic drugs: A review. Acta Neurol Scand 1996; 94: 367-77.
88. Shields WD, Saslow E. Myoclonic, atonic and absence seizures following institution of carbamazepine therapy in children. Neurology 1983; 33: 1487-9.
89. Kaminska A, Ickowicz A, Plouin P, Bru MF, Dellatolas G, Dulac O. Delineation of cryptogenic Lennox-Gastaut syndrome and myoclonic astatic epilepsy using multiple correspondence analysis. Epilepsy Res 1999; 36: 15-29.
90. Dravet C, Bureau M, Guerrini R, Giraud N, Roger J. Severe myoclonic epilepsy in infants. In: Roger J, Dravet C, Bureau M, Dreifuss FE, Wolf P, Perret A, eds. Epileptic Syndromes in Infancy Childhood and Adolescence. Paris: John Libbey Eurotext 2nd edition, 1992: 75-88.
91. Hurst DL. Severe myoclonic epilepsy of infants. Pediatr Neurol 1987; 3: 269-72.
92. Hurst DL. Expanded therapeutic range of valproate. Pediatr Neurol 1987; 3: 342-4.
93. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356: 1638-42.
94. Genton P, Guerrini R, Dravet C. The Lennox-Gastaut syndrome. In: Handbook of Clinical Neurology Vol. 73 (29). The Epilepsies. Part II: H. Meinardi Editor. Amsterdam: Elsevier Science, 2000: 211-22.
95. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997; 337: 1807-12.
96. Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood encephalopathy (the Lennox-Gastaut syndrome). Epilepsia 1997; 38: 68-73.
97. Timmings PL, Richens A. Lamotrigine as add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992; 32: 305-7.
98. Dubc O, Kaminska A. Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J Child Neurol 1987; 12 (suppl 1): S23-8.
99. Brodie MJ, Yuen AW. Lamotrigine substitution study: Evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997; 26: 423-32.
100. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of Felbamate in childhood epileptic encephalopathy (Lennox-Gastaut Syndrome). N Engl J Med 1993; 328: 29-33.
101. Ritter FJ, Dreifuss FE, Sackellars JC, et al. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29-33.
102. Siegel H, Kelley K, Stertz B, Reeves-Tyer P, Flamini R, Malow B, Gaillard WD, Ko D, Theodore WH. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsy Res 1999; 34: 91-7.
103. Pellock JM, Brodie MJ. Felbamate: 1997 Update. Epilepsia 1997; 38: 1261-4.
104. Schmidt D, Bourgeois B. A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf 2000; 22: 467-77.
105. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999; 52: 1882-7.
106. Freeman JM, Vining EP, Pillas DJ, et al. The efficacy of the ketogenic diet - 1998: A prospective evaluation of intervention in 150 children. Pediatrics 1998; 102: 1358-63.
107. Johsen SD, Tarby TJ, Sidell AD. Carbamazepine-induced seizures. Ann Neurol 1984; 16: 392-3.
108. Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996; 46: 852-3.
109. Riikonen R, Donner M. ACTH therapy in infantile spasms: Side effects. Arch Dis Child 1980; 55: 664-72.
110. Kusse MC, van Nieuwenhuizen O, van Huffelen AC, et al. The effect of non-depot ACTH on infantile spasms. Dev Med Child Neurol 1993; 35: 1067-73.
111. Chiron C, Dulac O, Luna D, Palacios L, Mondragon S, Beaumont D, Munford JP. Vigabatrin in infantile spasms. Lancet 1990; 335: 363-4.
112. Aicardi J, Sabril IS, Investigator and Peer Review Groups, et al. Vigabatrin as initial therapy for infantile spasms: A European retrospective survey. Epilepsia 1996; 37: 638-42.
113. Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999; 40: 1627-33.
114. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: A randomized prospective study. Epilepsia 1997; 38: 270-4.
115. Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomised trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26: 389-95.
116. Prats JM, Garaizar C, Rua MJ, et al. Infantile spasms treated with high doses of sodium valproate: Initial response and follow-up. Dev Med Child Neurol 1991; 33: 617-25.
117. Chamberlain MC. Nitrazepam for refractory infantile spasms and the Lennox-Gastaut syndrome. J Child Neurol 1996; 11: 31-4.
118. Gross-Tsur V, Banin E, Shahar E, Shalev RS, Lahat E. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000; 48: 60-4.
119. Vanhatalo S, Nousiainen I, Eriksson K, et al. Visual field constriction in 91 finnish children treated with vigabatrin. Epilepsia 2002; 43: 748-56.
120. Trevathan E. Infantile spasms and Lennox-Gastaut syndrome. J Child Neurol 2002; 17 (suppl 2): 2S9-22.